GetTopicDetailResponse(id=739013662af, topicName=Padcev, introduction=Padcev, content=null, image=null, comments=3, allHits=1112, url=https://h5.medsci.cn/topic?id=13662, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=98036, tagList=[TagDto(tagId=98036, tagName=Padcev)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1981827, encodeId=5657198182eab, content=<a href='/topic/show?id=739013662af' target=_blank style='color:#2F92EE;'>#Padcev#</a>, objectTitle=Padcev（enfortumab vedotin）在歐盟獲準(zhǔn)治療晚期尿路上皮癌, objectType=article, longId=724545, objectId=4673e2454541, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4673e2454541, replyNumber=0, likeNumber=94, createdTime=2022-07-28, rootId=0, userName=tm10051981, userId=76fa353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4673e2454541, moduleTitle=Padcev（enfortumab vedotin）在歐盟獲準(zhǔn)治療晚期尿路上皮癌, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=4673e2454541)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1981826, encodeId=59ef198182641, content=<a href='/topic/show?id=739013662af' target=_blank style='color:#2F92EE;'>#Padcev#</a>, objectTitle=PADCEV（enfortumab vedotin-ejfv）聯(lián)合Pembrolizumab治療晚期膀胱癌獲得的FDA突破性療法認(rèn)定, objectType=article, longId=188519, objectId=cccf188519dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cccf188519dd, replyNumber=0, likeNumber=96, createdTime=2020-03-23, rootId=0, userName=一葉知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cccf188519dd, moduleTitle=PADCEV（enfortumab vedotin-ejfv）聯(lián)合Pembrolizumab治療晚期膀胱癌獲得的FDA突破性療法認(rèn)定, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=cccf188519dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1981825, encodeId=8288198182502, content=<a href='/topic/show?id=739013662af' target=_blank style='color:#2F92EE;'>#Padcev#</a>, objectTitle=Seattle Genetics/Astellas的抗體-藥物偶聯(lián)物Padcev治療晚期尿路上皮癌，獲得FDA批準(zhǔn), objectType=article, longId=185039, objectId=2317185039ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2317185039ae, replyNumber=0, likeNumber=0, createdTime=2020-02-15, rootId=0, userName=tm10051981, userId=76fa353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2317185039ae, moduleTitle=Seattle Genetics/Astellas的抗體-藥物偶聯(lián)物Padcev治療晚期尿路上皮癌，獲得FDA批準(zhǔn), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=2317185039ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
